The DOI matches its Crossref record; 120 of the 120 references it cites were found in a registry or an index.
Molecular subtypes of pancreatic cancer
Open accessAbstract
Cancers that appear morphologically similar often have dramatically different clinical features, respond variably to therapy and have a range of outcomes. Compelling evidence now demonstrates that differences in the molecular pathology of otherwise indistinguishable cancers substantially impact the clinical characteristics of the disease. Molecular subtypes now guide preclinical and clinical therapeutic development and treatment in many cancer types. The ability to predict optimal therapeutic strategies ahead of treatment improves overall patient outcomes, minimizing treatment-related morbidity and cost. Although clinical decision making based on histopathological criteria underpinned by robust data is well established in many cancer types, subtypes of pancreatic cancer do not currently inform treatment decisions. However, accumulating molecular data are defining subgroups in pancreatic cancer with distinct biology and potential subtype-specific therapeutic vulnerabilities, providing the opportunity to define a de novo clinically applicable molecular taxonomy. This Review summarizes current knowledge concerning the molecular subtyping of pancreatic cancer and explores future strategies for using a molecular taxonomy to guide therapeutic development and ultimately routine therapy with the overall goal of improving outcomes for this disease.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“consensus has best coalesced around two major subtypes, classical and basal-like, with some populations showing mixed features135”
From Pancreatic cancer: Advances and challenges (2023) · cites this paper as [135]
Citations
Cites
Molecular portraits of human breast tumours
Perou, C., Sørlie, T., Eisen, M., van de Rijn, M., Jeffrey, S., Rees, C. A., Pollack, J., Ross, D., Johnsen, H., Akslen, L., et al. (2000) · Nature · doi:10.1038/35021093 · Cited by 16,551
Siegel, R. L., Miller, K. D., & Jemal, A. (2017) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21387 · Cited by 14,712
Slamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Pegram, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103153441101 · Cited by 11,500
Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling
Alizadeh, A. A., Eisen, M. B., Davis, R. E., Ma, C., Lossos, I. S., Rosenwald, A., Boldrick, J. C., Sabet, H., Tran, T., Yu, X., et al. (2000) · Nature · doi:10.1038/35000501 · Cited by 9,925
Signatures of mutational processes in human cancer
Initiative, A. P. C. G., Alexandrov, L. B., ICGC Breast Cancer Consortium, ICGC MMML-Seq Consortium, PedBrain, I., Nik-Zainal, S., Wedge, D. C., Aparicio, S. A. J. R., Behjati, S., Biankin, A. V., et al. (2013) · Nature · doi:10.1038/nature12477 · Cited by 9,660
Self-citationVogelstein, B., Papadopoulos, N., Velculescu, V. E., Zhou, S., Diaz, L. A., & Kinzler, K. W. (2013) · Science · doi:10.1126/science.1235122 · Cited by 7,863
Comprehensive genomic characterization defines human glioblastoma genes and core pathways
The Cancer Genome Atlas Research Network (2008) · Nature · doi:10.1038/nature07385 · Cited by 7,735
Spencer, P. M., Cameron, J. L., & Lin, L. (2000) · Cited by 7,202
Rahib, L., Smith, B. D., Aizenberg, R., Rosenzweig, A. B., Fleshman, J. M., & Matrisian, L. M. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-0155 · Cited by 7,094
Comprehensive molecular profiling of lung adenocarcinoma
The Cancer Genome Atlas Research Network (2014) · Nature · doi:10.1038/nature13385 · Cited by 5,732
Self-citation
Research works printed but not linked: 1
- Ryan, D. P., Hong, T. S. & Bardeesy, N. Pancreatic adenocarcinoma. N. Engl. J. Med. 371, 2140–2141 (2014).
Cited by
Sorted by citations
Items 101–200 of 895
Pancreatic Ductal Adenocarcinoma: Molecular Pathology and Predictive Biomarkers
Taherian, M., Wang, H., & Wang, H. (2022) · Cells · doi:10.3390/cells11193068 · Cited by 52
Sadozai, H., Acharjee, A., Eppenberger‐Castori, S., Gloor, B., Gruber, T., Schenk, M., & Karamitopoulou, E. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.643529 · Cited by 47
HMGA1 induces FGF19 to drive pancreatic carcinogenesis and stroma formation
Chia, L., Wang, B., Kim, J., Luo, L., Shuai, S., Herrera, I., Chen, S. Y., Li, L., Xian, L., Huso, T. H., et al. (2023) · Journal of Clinical Investigation · doi:10.1172/jci151601 · Cited by 52
Shinkawa, T., Ohuchida, K., Mochida, Y., Sakihama, K., Iwamoto, C., Abe, T., Ideno, N., Mizuuchi, Y., Shindo, K., Ikenaga, N., et al. (2022) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-022-02301-9 · Cited by 41
Vaes, R. D. W., van Dijk, D. P. J., Welbers, T. T. J., Blok, M. J., Aberle, M. R., Heij, L. R., Boj, S. F., Damink, S. W. M. O., & Rensen, S. S. (2020) · Journal of Cachexia Sarcopenia and Muscle · doi:10.1002/jcsm.12627 · Cited by 48
Ferroptosis in gastrointestinal cancer: from mechanisms to implications
Zhang, R., Kang, R., & Tang, D. (2023) · Cancer Letters · doi:10.1016/j.canlet.2023.216147 · Cited by 46
Role of non-coding RNAs in tumor progression and metastasis in pancreatic cancer
Sempere, L. F., Powell, K., Rana, J., Brock, A. A., & Schmittgen, T. D. (2021) · Cancer and Metastasis Reviews · doi:10.1007/s10555-021-09995-x · Cited by 45
Papargyriou, A., Najajreh, M., Cook, D. P., Maurer, C. H., Bärthel, S., Messal, H. A., Ravichandran, S. K., Richter, T., Knolle, M. A., Metzler, T., et al. (2024) · Nature Biomedical Engineering · doi:10.1038/s41551-024-01273-9 · Cited by 45
SEOM clinical guidelines for pancreatic and biliary tract cancer (2020)
Gómez‐España, M. A., Montés, A. F., García‐Carbonero, R., Macarulla, T. M., Maurel, J., Martín, Á., Pazo-Cid, R., Vera, R., Carrato, A., & Feliú, J. (2021) · Clinical & Translational Oncology · doi:10.1007/s12094-021-02573-1 · Cited by 45
Breaking the stromal barrier in pancreatic cancer: Advances and challenges
Chakkera, M., Foote, J. B., Farran, B., & Nagaraju, G. P. (2023) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2023.189065 · Cited by 48
Pancreatic cancer: molecular pathogenesis and emerging therapeutic strategies
Rozengurt, E., & Eibl, G. (2026) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02499-y · Cited by 49
Shabana, A. M., Kambhampati, S. P., Hsia, R., Kannan, R. M., & Kokkoli, E. (2020) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2020.120139 · Cited by 44
Abd-El-Halim, Y. M., Kaoutari, A. E., Silvy, F., Rubis, M., Bigonnet, M., Roques, J., Cros, J. F., Nicolle, R., Iovanna, J., Dusetti, N., et al. (2021) · EBioMedicine · doi:10.1016/j.ebiom.2021.103541 · Cited by 44
Ruggeri, J. M., Franco-Barraza, J., Sohail, A., Zhang, Y., Long, D., Pasca di Magliano, M., Cukierman, E., Fridman, R., & Crawford, H. C. (2020) · The American Journal of Pathology · doi:10.1016/j.ajpath.2020.03.020 · Cited by 40
Dreyer, S. B., Jamieson, N. B., Evers, L., Duthie, F. R., Cooke, S., Marshall, J., Beraldi, D., Knight, S. R., Upstill‐Goddard, R., Dickson, E. J., et al. (2019) · Chinese Clinical Oncology · doi:10.21037/cco.2019.04.06 · Cited by 43
Self-citationAssessment of spatial transcriptomics for oncology discovery
Lyubetskaya, A., Rabe, B. A., Fisher, A., Lewin, A. C., Neuhaus, I., Brett, C., Brett, T., Pereira, E. R., Golhar, R., Kebede, S., et al. (2022) · Cell Reports Methods · doi:10.1016/j.crmeth.2022.100340 · Cited by 42
Precision medicine in pancreatic cancer: treating every patient as an exception
Herbst, B. T., & Zheng, L. (2019) · The Lancet. Gastroenterology & hepatology · doi:10.1016/s2468-1253(19)30175-x · Cited by 42
Gupta, N., & Yelamanchi, R. (2021) · World Journal of Gastroenterology · doi:10.3748/wjg.v27.i23.3158 · Cited by 47
Deep Subspace Mutual Learning for cancer subtypes prediction
Yang, B., Xin, T., Pang, S., Wang, M., & Wang, Y.-J. (2021) · Bioinformatics · doi:10.1093/bioinformatics/btab625 · Cited by 40
Progress on diagnostic and prognostic markers of pancreatic cancer
YANG, H., Li, W., Ren, L., Yang, Y., Zhang, Y., Ge, B., Li, S., Zheng, X., Liu, J., Zhang, S., et al. (2023) · Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics · doi:10.32604/or.2023.028905 · Cited by 43
Deep multi-view contrastive learning for cancer subtype identification
Chen, W., Wang, H., & Liang, C. (2023) · Briefings in Bioinformatics · doi:10.1093/bib/bbad282 · Cited by 42
Storrs, E. P., Chati, P., Usmani, A., Sloan, I. H., Krasnick, B. A., Babbra, R. K., Harris, P. K. W., Sachs, C. M., Qaium, F., Chatterjee, D., et al. (2023) · npj Precision Oncology · doi:10.1038/s41698-023-00455-z · Cited by 48
Perioperative Modified FOLFIRINOX for Resectable Pancreatic Cancer
Cecchini, M., Salem, R. R., Robert, M. E., Czerniak, S., Bláha, O., Zelterman, D. A., Rajaei, M., Townsend, J. P., Cai, G., Chowdhury, S., et al. (2024) · JAMA Oncology · doi:10.1001/jamaoncol.2024.1575 · Cited by 46
Repurposing metformin for the treatment of gastrointestinal cancer
Júnior, A. D. D. C., Bragagnoli, A. S. C., Costa, F. O., & Carvalheira, J. B. C. (2021) · World Journal of Gastroenterology · doi:10.3748/wjg.v27.i17.1883 · Cited by 42
Frailty is associated with poor prognosis after resection for pancreatic cancer
Mima, K., Hayashi, H., Nakagawa, S., Matsumoto, T., Kinoshita, S., Matsumura, K., Kitamura, F., Uemura, N., Nakao, Y., Itoyama, R., et al. (2021) · International Journal of Clinical Oncology · doi:10.1007/s10147-021-01983-z · Cited by 40
Alexovič, M., Uličná, C., Sabó, J., & Davalieva, K. (2023) · PROTEOMICS - CLINICAL APPLICATIONS · doi:10.1002/prca.202300072 · Cited by 40
Kalisvaart, M., Broadhurst, D., Marcon, F., Pandé, R., Schlegel, A. A., Sutcliffe, R. P., Marudanayagam, R., Mirza, D. F., Chatzizacharias, N. A., Abradelo, M., et al. (2020) · HPB · doi:10.1016/j.hpb.2020.01.005 · Cited by 40
Thompson, E. D., Roberts, N. J., Wood, L. D., Eshleman, J. R., Goggins, M., Kern, S. E., Klein, A. P., & Hruban, R. H. (2020) · Modern Pathology · doi:10.1038/s41379-020-0629-6 · Cited by 41
Randazzo, O., Papini, F., Mantini, G., Gregori, A., Parrino, B., Liu, D., Cascioferro, S., Carbone, D., Peters, G. J., Frampton, A. E., et al. (2020) · Cancers · doi:10.3390/cancers12113206 · Cited by 39
Ohara, Y., Tang, W., Liu, H., Yang, S., Dorsey, T. H., Cawley, H., Moreno, P., Chari, R., Guest, M., Azizian, A., et al. (2023) · Cell Reports · doi:10.1016/j.celrep.2023.113434 · Cited by 41
Liu, J., Liu, Q., Zhang, X., Cui, M., Li, T., Zhang, Y., & Liao, Q. (2021) · Cancer Cell International · doi:10.1186/s12935-021-01824-z · Cited by 39
Genomic Heterogeneity of Pancreatic Ductal Adenocarcinoma and Its Clinical Impact
Gutiérrez, M. L., Muñoz‐Bellvís, L., & Órfão, A. (2021) · Cancers · doi:10.3390/cancers13174451 · Cited by 41
Peschke, K., Jakubowsky, H., Schäfer, A., Maurer, H. C., Lange, S., Orben, F., Bernad, R., Harder, F. N., Eiber, M., Öllinger, R., et al. (2022) · EMBO Molecular Medicine · doi:10.15252/emmm.202114876 · Cited by 37
NOXA expression drives synthetic lethality to RUNX1 inhibition in pancreatic cancer
Doffo, J., Bamopoulos, S. A., Köse, H., Orben, F., Zang, C., Pons, M., den Dekker, A. T., Brouwer, R. W. W., Baluapuri, A., Habringer, S., et al. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2105691119 · Cited by 36
Targeted Therapies in Pancreatic Cancer: A New Era of Precision Medicine
Li, B., Zhang, Q., Castaneda, C. N., & Cook, S. M. (2024) · Biomedicines · doi:10.3390/biomedicines12102175 · Cited by 38
Dhara, S., Chhangawala, S., Chintalapudi, H., Aşkan, G., Aveson, V. G., Massa, A. L., Zhang, L., Torres, D., Makohon-Moore, A. P., Lecomte, N., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-23237-2 · Cited by 37
Autophagy Contributes to Metabolic Reprogramming and Therapeutic Resistance in Pancreatic Tumors
Reyes‐Castellanos, G., Hadi, N. A., & Carrier, A. (2022) · Cells · doi:10.3390/cells11030426 · Cited by 41
Decoding the basis of histological variation in human cancer
Fujii, M., Sekine, S., & Sato, T. (2023) · Nature reviews. Cancer · doi:10.1038/s41568-023-00648-5 · Cited by 35
Zhu, X., Kong, Q., Niu, X., Chen, L., & Ge, C. (2020) · International Journal of Nanomedicine · doi:10.2147/ijn.s253599 · Cited by 36
Jeong, J., Kim, T., Kim, J., Choi, H. W., Kim, E. J., Yoo, H. J., Lee, S., Jun, H. R., Yoo, W., Kim, S., et al. (2020) · Cancers · doi:10.3390/cancers12092346 · Cited by 36
The SUMO pathway in pancreatic cancer: insights and inhibition
Schneeweis, C., Hassan, Z., Schick, M., Keller, U. B., & Schneider, G. (2020) · British Journal of Cancer · doi:10.1038/s41416-020-01119-6 · Cited by 36
Swietlik, J. J., Bärthel, S., Falcomatà, C., Fink, D., Sinha, A., Cheng, J., Ebner, S., Landgraf, P., Dieterich, D. C., Daub, H., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-38171-8 · Cited by 38
Principe, D. R., Underwood, P. W., Kumar, S., Timbers, K. E., Koch, R. M., Trevino, J. G., Munshi, H. G., & Rana, A. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.806963 · Cited by 35
Principe, D. R. (2022) · Cancers · doi:10.3390/cancers14040897 · Cited by 38
Perera, S., Jang, G. H., Wang, Y., Kelly, D., Allen, M. J., Zhang, A. X. W., Denroche, R. E., Dodd, A., Ramotar, S., Hutchinson, S., et al. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-2576 · Cited by 35
BHLHE40 Inhibits Ferroptosis in Pancreatic Cancer Cells via Upregulating SREBF1
Cao, Y., Wang, X., Liu, Y., Liu, P., Qin, J., Zhu, Y., Zhai, S., Jiang, Y., Liu, Y., Han, L., et al. (2023) · Advanced Science · doi:10.1002/advs.202306298 · Cited by 36
Role of targeted immunotherapy for pancreatic ductal adenocarcinoma (PDAC) treatment: An overview
Panchal, K., Sahoo, R. K., Gupta, U. D., & Chaurasiya, A. (2021) · International Immunopharmacology · doi:10.1016/j.intimp.2021.107508 · Cited by 33
Favorable tumor biology in locally advanced pancreatic cancer—beyond CA19-9
Kinny‐Köster, B., Habib, J. R., Wolfgang, C. L., He, J. P., & Javed, A. A. (2021) · Journal of Gastrointestinal Oncology · doi:10.21037/jgo-20-426 · Cited by 34
Guo, Y., Zhu, H., Xiao, Y., Guo, H., Lin, M., Yuan, Z., Yang, X., Huang, Y., Zhang, Q., & Bai, Y. (2022) · Cell Death and Disease · doi:10.1038/s41419-022-04573-7 · Cited by 33
Activation of STING in the pancreatic tumor microenvironment: A novel therapeutic opportunity
Chamma, H., Vila, I. K., Taffoni, C., Turtoï, A., & Laguette, N. (2022) · Cancer Letters · doi:10.1016/j.canlet.2022.215694 · Cited by 33
Hwang, W. L., Jagadeesh, K. A., Guo, J. A., Hoffman, H. I., Yadollahpour, P., Mohan, R. R., Drokhlyansky, E., Wittenberghe, N. V., Ashenberg, O., Farhi, S. L., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.08.25.267336 · Cited by 35
Comparing Redox and Intracellular Signalling Responses to Cold Plasma in Wound Healing and Cancer
Abdo, A. I., & Kopecki, Z. (2024) · Current Issues in Molecular Biology · doi:10.3390/cimb46050294 · Cited by 37
Pharmacogenetics of treatments for pancreatic cancer
Hassouni, B. E., Petri, G. L., Liu, D., Cascioferro, S., Parrino, B., Hassan, W. U., Diana, P., Ali, A., Frampton, A. E., & Giovannetti, E. (2019) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2019.1620731 · Cited by 34
de Oliveira, G., Freire, P. P., Cury, S. S., de Moraes, D., Oliveira, J. S., Dal‐Pai‐Silva, M., Reis, P. P., & Carvalho, R. F. (2020) · Cancers · doi:10.3390/cancers12030716 · Cited by 34
CD36 and CD97 in Pancreatic Cancer versus Other Malignancies
Tănase, C., Gheorghișan-Gălățeanu, A.-A., Popescu, I. D., Mihai, S., Codrici, E., Albulescu, R., & Hinescu, M. E. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21165656 · Cited by 32
The Gustatory Sensory G-Protein GNAT3 Suppresses Pancreatic Cancer Progression in Mice
Hoffman, M. T., Kemp, S. B., Salas-Escabillas, D. J., Zhang, Y., Steele, N. G., The, S., Long, D., Benitz, S., Wei, Y., Margolskee, R. F., et al. (2020) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2020.08.011 · Cited by 31
Jain, P., Dvorkin‐Gheva, A., Mollen, E., Malbeteau, L., Xie, M. H., Jessa, F., Dhavarasa, P., Chung, S., Brown, K. R., Jang, G. H., et al. (2021) · Science Advances · doi:10.1126/sciadv.abf7114 · Cited by 33
Caruso, G., Privitera, A., Antunes, B. M., Lazzarino, G., Lunte, S. M., Aldini, G., & Caraci, F. (2022) · Molecules · doi:10.3390/molecules27144452 · Cited by 34
Shinkawa, T., Ohuchida, K., & Nakamura, M. (2022) · Cancers · doi:10.3390/cancers14163994 · Cited by 32
Lencioni, G., Gregori, A., Toledo, B., Rebelo, R., Immordino, B., Amrutkar, M., Xavier, C. P. R., Kocijancic, A., Pandey, D. P., Perán, M., et al. (2024) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2024.09.002 · Cited by 32
Wu, W., Miao, Y., Yang, Y., Lou, W., & Zhao, Y. (2021) · Journal of Pancreatology · doi:10.1097/jp9.0000000000000086 · Cited by 29
Suurmeijer, J. A., Soer, E. C., Dings, M. P. G., Kim, Y., Strijker, M., Bonsing, B. A., Brosens, L. A. A., Busch, O. R., Groen, J. V., Halfwerk, J. B. G., et al. (2022) · British journal of surgery · doi:10.1093/bjs/znac272 · Cited by 30
Moon, J., Ediriweera, M. K., Ryu, J., Kim, H. J., & Cho, S. K. (2021) · Oncology Reports · doi:10.3892/or.2021.7924 · Cited by 31
Zhang, X., Feng, S., Wang, Q., Huang, H., Chen, R., Xie, Q., Zhang, W., Wang, A., Zhang, S., Wang, L.-J., et al. (2021) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.16281 · Cited by 31
Rozengurt, E., & Eibl, G. (2021) · Cancers · doi:10.3390/cancers13205126 · Cited by 31
Tuntithavornwat, S., Shea, D. J., Wong, B. S., Guardia, T., Lee, S. J., Yankaskas, C. L., Zheng, L., Kontrogianni‐Konstantopoulos, A., & Κωνσταντόπουλος, Κ. (2021) · Cancer Letters · doi:10.1016/j.canlet.2021.11.016 · Cited by 30
Molecular mechanisms of pancreatic cancer liver metastasis: the role of PAK2
Yang, H., Li, Z., Zhu, S., Wang, W., Zhang, J., Zhao, D., Zhang, M., Zhu, W., Xu, W., & Xu, C. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1347683 · Cited by 30
Ruta, V., Naro, C., Pieraccioli, M., Leccese, A., Archibugi, L., Cesari, E., Panzeri, V., Allgöwer, C., Arcidiacono, P. G., Falconi, M., et al. (2024) · Cell Reports Medicine · doi:10.1016/j.xcrm.2024.101411 · Cited by 29
Targeting SRC Kinase Signaling in Pancreatic Cancer Stem Cells
Alcalá, S., Mayoral-Varo, V., Ruíz-Cañas, L., López-Gil, J. C., Heeschen, C., Martı́n-Pérez, J., & Sáinz, B. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21207437 · Cited by 29
Subtyping for pancreatic cancer precision therapy
Huang, X., Zhang, G., & Liang, T. (2022) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2022.03.005 · Cited by 32
Dorn, Á., Glaß, M., Neu, C. T., Heydel, B., Hüttelmaier, S., Gutschner, T., & Hämmerle, M. (2020) · Cancers · doi:10.3390/cancers12051227 · Cited by 27
Molecular Mechanisms and Potential Therapeutic Reversal of Pancreatic Cancer-Induced Immune Evasion
Gan, L.-L., Hii, L., Wong, S. F., Leong, C., & Mai, C. (2020) · Cancers · doi:10.3390/cancers12071872 · Cited by 28
Oshi, M., Tokumaru, Y., Patel, A. P., Yan, L., Matsuyama, R., Endo, I., Katz, M. H. G., & Takabe, K. (2020) · Cancers · doi:10.3390/cancers12123635 · Cited by 28
Pancreatic Organoids for Regenerative Medicine and Cancer Research
Casamitjana, J., Espinet, E., & Rovira, M. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.886153 · Cited by 29
Pan, P., Qin, G., Wang, B., Yu, H., Chen, J., Liu, J., Bing, K., Shen, J., Ren, D., Zhao, Y., et al. (2022) · Cancer Research · doi:10.1158/0008-5472.can-21-4362 · Cited by 31
The resurgence of the Adora2b receptor as an immunotherapeutic target in pancreatic cancer
Strickland, L. N., Faraoni, E. Y., Ruan, W., Yuan, X., Eltzschig, H. K., & Bailey, J. M. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1163585 · Cited by 29
Milan, M., Diaferia, G. R., & Natoli, G. (2021) · The EMBO Journal · doi:10.15252/embj.2020107206 · Cited by 27
Cortesi, A., Gandolfi, F., Arco, F., Chiaro, P. D., Valli, E., Polletti, S., Noberini, R., Gualdrini, F., Attanasio, S., Citron, F., et al. (2024) · Science Advances · doi:10.1126/sciadv.adk5386 · Cited by 29
Driver Mutations in Pancreatic Cancer and Opportunities for Targeted Therapy
Olaoba, O. T., Adelusi, T. I., Yang, M. J., Maidens, T., Kimchi, E. T., Staveley-O’Carroll, K. F., & Li, G. (2024) · Cancers · doi:10.3390/cancers16101808 · Cited by 28
Mu, W., Xu, Y., Gu, P., Wang, W., Li, J., Ge, Y., & Wang, H. (2020) · Engineering · doi:10.1016/j.eng.2020.08.013 · Cited by 26
Detection of Chemotherapy-resistant Pancreatic Cancer Using a Glycan Biomarker, sTRA
Gao, C., Wisniewski, L., Liu, Y., Staal, B., Beddows, I., Plenker, D., Aldakkak, M., Hall, J., Barnett, D., Gouda, M. K., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-2475 · Cited by 26
Zhang, C., Huang, L., Xiong, J., Xie, L., Ying, S., You, J., Yao, Y., Song, X., Zeng, Z., & Yuan, J. (2021) · PLoS ONE · doi:10.1371/journal.pone.0247752 · Cited by 26
Shi, W., Li, C., Wartmann, T., Kahlert, C., Du, R., Perrakis, A., Brunner, T. B., Croner, R. S., & Kahlert, U. D. (2022) · Journal of Personalized Medicine · doi:10.3390/jpm12030478 · Cited by 26
The biological behavior of tRNA-derived fragment tRF-Leu-AAG in pancreatic cancer cells
Sui, S., Wang, Z., Cui, X., Jin, L., & Zhu, C. (2022) · Bioengineered · doi:10.1080/21655979.2022.2064206 · Cited by 26
A Tumor Microenvironment Model of Pancreatic Cancer to Elucidate Responses toward Immunotherapy
Kast, V., Nadernezhad, A., Pette, D., Gabrielyan, A., Fusenig, M., Honselmann, K. C., Stange, D. E., Werner, C., & Loessner, D. (2022) · Advanced Healthcare Materials · doi:10.1002/adhm.202201907 · Cited by 27
Current status of molecular diagnostic approaches using liquid biopsy
Takahashi, K., Takeda, Y., Ono, Y., Isomoto, H., & Mizukami, Y. (2023) · Journal of Gastroenterology · doi:10.1007/s00535-023-02024-4 · Cited by 26
Liaki, V., Barrambana, S., Kostopoulou, M., Lechuga, C. G., Zamorano-Domínguez, E., Acosta, D., Morales-Cacho, L., Álvarez, R., Sun, P., Rosas-Pérez, B., et al. (2025) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2523039122 · Cited by 27
RetractedPapalampros, A., Vailas, M. G., Ntostoglou, K., Chiloeches, M. L., Sakellariou, S., Chouliari, N. V., Samaras, M. G., Veltsista, P. D., Theodorou, S. D. P., Margetis, A., et al. (2020) · Cancers · doi:10.3390/cancers12071825 · Cited by 25
Timmer, F. E. F., Geboers, B., Nieuwenhuizen, S., Schouten, E. A. C., Dijkstra, M., de Vries, J. J. J., van den Tol, M. P., Meijerink, M. R., & Scheffer, H. J. (2021) · Cancers · doi:10.3390/cancers13071608 · Cited by 45
van Roey, R., Brabletz, T., Stemmler, M. P., & Armstark, I. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.753456 · Cited by 26
Torre-Healy, L. A., Kawalerski, R. R., Oh, K., Chrastecka, L., Peng, X. L., Aguirre, A. J., Rashid, N. U., Yeh, J. J., & Moffitt, R. A. (2023) · Communications Biology · doi:10.1038/s42003-023-04461-6 · Cited by 28
Liu, X., Gündel, B., Li, X., Liu, J., Wright, A., Löhr, M., Arvidsson, G., & Heuchel, R. (2021) · Translational Oncology · doi:10.1016/j.tranon.2021.101107 · Cited by 24
Nimgaonkar, V. U., Krishna, V., Krishna, V., Tiu, E., Joshi, A., Vrabac, D., Bhambhvani, H. P., Smith, K., Johansen, J. S., Makawita, S., et al. (2023) · Cell Reports Medicine · doi:10.1016/j.xcrm.2023.101013 · Cited by 28
Self-citationGhidini, M., Petrillo, A., Salati, M., Khakoo, S. S., Varricchio, A., Tomasello, G., Grossi, F., & Petrelli, F. (2019) · Cancers · doi:10.3390/cancers11081095 · Cited by 24
Is there a CDKN2A-centric network in pancreatic ductal adenocarcinoma?
Wu, C. L., Yang, P., Liu, B., & Tang, Y. (2020) · OncoTargets and Therapy · doi:10.2147/ott.s232464 · Cited by 29
Semaan, A., Bernard, V., Lee, J. J., Wong, J., Huang, J. H., Swartzlander, D. B., Stephens, B. M., Monberg, M. E., Weston, B. R., Bhutani, M. S., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-2667 · Cited by 25
Ghareyazi, A., Mohseni, A., Dashti, H., Beheshti, A., Dehzangi, A., Rabiee, H. R., & Alinejad‐Rokny, H. (2021) · Cancers · doi:10.3390/cancers13174376 · Cited by 24
Gong, S., Xiong, L., Luo, Z., Yin, Q., Huang, M. B., Zhou, Y., & Li, J. (2022) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2022.11430 · Cited by 24
RetractedChen, H., Zhang, J., Sun, X., Wang, Y., & Qian, Y. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.901207 · Cited by 25
Mouse models of Kras activation in gastric cancer
Won, Y., & Choi, E.-Y. K. (2022) · Experimental & Molecular Medicine · doi:10.1038/s12276-022-00882-1 · Cited by 23
Metadata
- Authors
- Collisson, E. A., Bailey, P., Chang, D. K., & Biankin, A. V.
- Affiliations
- University of California, San Francisco (US)
- University of Glasgow (GB)
- Glasgow Royal Infirmary (GB)
- Corresponding author
- Biankin, Andrew V.
- Venue
- Nature Reviews Gastroenterology & Hepatology
- Published
- 2019-02-04
- Volume
- 16
- Issue
- 4
- Pages
- 207-220
- ISSN
- 1759-5045 (ISSN-L)
- 1759-5053
- OpenAlex
- W2913268845
- Cited by
- 892
- References
- 119
- Citations by year
- 2026: 69 · 2025: 87 · 2024: 168 · 2023: 142 · 2022: 135 · 2021: 157 · 2020: 104 · 2019: 28
- FWCI
- 10.11
- Type
- journal article
- Language
- en
- Open access
- green
- eprints.gla.ac.uk
- Licence
- cc-by-sa
- www.springer.com/tdm (tdm)
- Locations
- Nature Reviews Gastroenterology & Hepatology (publishedVersion)
- PubMed (publishedVersion)
- ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) (submittedVersion, cc-by-sa)
- Funders
- Pancreatic Cancer UK (FLF2015_04_GLASGOW)
- Wellcome Trust (103721/Z/14/Z)
- Cancer Research UK (23526, 17263)
- Medical Research Council (MR/N005813/1)
- Topics
- Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Health Sciences › Medicine › Surgery › Pancreatitis Pathology and Treatment
- Keywords
- pancreatic cancer, molecular subtypes, molecular taxonomy, molecular subtyping, therapeutic targeting, treatment response, histological classification
- MeSH terms
- Clinical Decision-Making, Genetic Markers, Humans, Pancreatic Neoplasms, Prognosis, Biomarkers, Tumor, Risk Assessment, Carcinoma, Pancreatic Ductal
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
